Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 14, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2021 16:15 ET
|
Yumanity Therapeutics Inc
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics to Present at the H.C. Wainwright 23rd Global Investment Conference
September 09, 2021 08:00 ET
|
Yumanity Therapeutics Inc
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Appoints Michael D. Wyzga as Chief Financial Officer and Announces Inducement Grants
August 16, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
August 12, 2021 16:15 ET
|
Yumanity Therapeutics Inc
YTX-7739 shown to inhibit its novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Topline results for the YTX-7739 Phase 1b...
Yumanity Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 06, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Appoints Devin W. Smith as General Counsel
June 14, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, June 14, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics to Present at Upcoming Virtual Investor Conferences
May 27, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, May 27, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics’ R&D Day Reviews Near-Term Value Drivers and Pipeline-Generating Discovery Engine
May 17, 2021 16:05 ET
|
Yumanity Therapeutics Inc
Clinical efforts expanding to three programs consisting of: the on-going Phase 1b portion of the YTX-7739 Phase 1 program in Parkinson’s disease patients with top line results expected in mid-2021...
Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments
May 13, 2021 07:00 ET
|
Yumanity Therapeutics Inc
Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease Initiated dosing in Phase...